Cargando…
A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor
BACKGROUND: Available essential tremor (ET) therapies have limitations. OBJECTIVES: The objective of this study was to evaluate CX‐8998, a selective T‐type calcium channel modulator, in essential tremor. METHODS: Patients 18–75 years old with moderate to severe essential tremor were randomized 1:1 t...
Autores principales: | Papapetropoulos, Spyros, Lee, Margaret S., Versavel, Stacey, Newbold, Evan, Jinnah, Hyder A., Pahwa, Rajesh, Lyons, Kelly E., Elble, Rodger, Ondo, William, Zesiewicz, Theresa, Hedera, Peter, Handforth, Adrian, Elder, Jenna, Versavel, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451783/ https://www.ncbi.nlm.nih.gov/pubmed/33764619 http://dx.doi.org/10.1002/mds.28584 |
Ejemplares similares
-
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection
por: Papapetropoulos, Spyros, et al.
Publicado: (2019) -
Methodological Issues in Clinical Drug Development for Essential Tremor
por: Carranza, Michael A., et al.
Publicado: (2012) -
Defining Dystonic Tremor
por: Elble, Rodger J
Publicado: (2013) -
Bayesian Interpretation of Essential Tremor Plus
por: Elble, Rodger J.
Publicado: (2022) -
Slow Orthostatic Tremor and the Case for Routine Electrophysiological Evaluation of All Tremors
por: Torres-Russotto, Diego, et al.
Publicado: (2019)